Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Oncorena.

    Client Virtual Booth

    ONCORENA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Oncorena
    Sweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Medicon Village, Scheeletorget 1 SE‑223 81 Lund
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.oncorena.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/oncorena-ab/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Oncorena's First Patient Treated with ONC175 (Orellanine) in Clinical Phase I/II Trial in Patients with Metastatic Renal Cancer and Dialysis at Karolins...

    Details:

    ONC175 (orellanine) is the highly selective organ-targeted chemotherapy with potent anti-tumor effects metastatic renal cancer. The interim data from phase 1b further strengthens the previously reported promising safety and efficacy data.


    Lead Product(s): Orellanine

    Therapeutic Area: Oncology Product Name: ONC175

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 04, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Oncorena Initiates the Phase I-II Clinical Trial with Orellanine in Advanced Kidney Cancer Patients at Karolinska University Hospital in Sweden

    Details:

    Phase I-II clinical trial of the first-in-class compound Orellanine, found in mushrooms of the Cortinarius family initiated and demonstrated powerful anti-tumor effects on metastatic kidney cancer in different preclinical models.


    Lead Product(s): Orellanine

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Karolinska University Hospital

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 01, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Oncorena Secures Financing of the Company's Continued Development of Orellanine, a Potential Breakthrough Therapy for Advanced Renal Cancer

    Details:

    The capital will primarily fund Oncorena’s first clinical study, a phase I/II study with orellanine in patients with advanced kidney cancer undergoing dialysis. Orellanine is found in mushrooms of the Cortinarius family.


    Lead Product(s): Orellanine

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Linc AB

    Deal Size: $17.7 million Upfront Cash: Undisclosed

    Deal Type: Financing December 23, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Oncorena Receives Approval of First in Patient Trial with Orellanine as a Potential Breakthrough Therapy in Metastatic Renal Cancer Patients

    Details:

    Preclinical evidence shows that orellanine, a well known fungus toxin, specifically exerts powerful anti-tumor effects on metastatic renal cancer in different preclinical models.


    Lead Product(s): Orellanine

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 01, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search